Silo pharma announces positive results for intranasal ptsd treatment

Intranasal delivery of spc-15 shows rapid and effective drug exposure for ptsd therapy sarasota, fl, april 23, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (pk) study of spc-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (ptsd). the pk study was conducted as part of non-glp small animal dose-ranging study of spc-15 completed in february 2024.
SILO Ratings Summary
SILO Quant Ranking